Close Menu

NEW YORK (GenomeWeb) — Biotheranostics announced today that its Breast Cancer Index (BCI) genomic test has has been issued an expanded local coverage determination (LCD) by Medicare contractor Noridian.

The PCR-based test evaluates the expression of 11 genes to help physicians predict the risk of late disease recurrence and identify which early-stage breast cancer patients are likely to benefit from continuing adjuvant endocrine therapy beyond five years.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.